Agenus (NASDAQ:AGEN) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Agenus (NASDAQ:AGEN) from a buy rating to a strong-buy rating in a research report sent to investors on Sunday morning.

AGEN has been the topic of a number of other research reports. Weiss Ratings raised shares of Agenus from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday. Zacks Research cut Agenus from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 11th. B. Riley Financial reissued a “buy” rating and set a $14.00 price objective (up from $8.00) on shares of Agenus in a report on Thursday, July 30th. Finally, HC Wainwright boosted their price objective on Agenus from $23.00 to $30.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $19.50.

Agenus Trading Down 2.4%

AGEN opened at $6.83 on Friday. The company’s 50 day moving average is $4.61 and its 200-day moving average is $3.87. Agenus has a 1-year low of $2.71 and a 1-year high of $8.85. The company has a market cap of $307.49 million, a P/E ratio of 2.65 and a beta of 1.41.

Agenus (NASDAQ:AGEN) last released its quarterly earnings data on Friday, August 7th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.06). The company had revenue of $34.52 million for the quarter, compared to analyst estimates of $34.00 million. Agenus had a negative return on equity of 45.12% and a net margin of 69.33%. On average, equities analysts forecast that Agenus will post -0.17 EPS for the current year.

Institutional Investors Weigh In On Agenus

Hedge funds have recently added to or reduced their stakes in the business. EP Wealth Advisors LLC acquired a new position in Agenus in the 4th quarter valued at approximately $31,000. Jump Financial LLC bought a new position in shares of Agenus during the second quarter valued at $55,000. R Squared Ltd acquired a new position in shares of Agenus during the fourth quarter worth $41,000. Squarepoint Ops LLC acquired a new position in shares of Agenus during the third quarter worth $54,000. Finally, Redwood Family Wealth LLC bought a new stake in shares of Agenus in the fourth quarter worth $44,000. 61.46% of the stock is currently owned by institutional investors and hedge funds.

More Agenus News

Here are the key news stories impacting Agenus this week:

• Positive Sentiment: HC Wainwright raised its Q3 and Q4 2026 EPS forecasts to $0.05 from $0.03 and $0.01, respectively. The firm also improved its FY2026 estimate to a loss of $0.15 per share from $0.22 and reiterated a Buy rating with a $30 price target, indicating significant potential upside if Agenus meets the estimates.
• Positive Sentiment: Agenus expanded its board from six to seven members and appointed Rom… as a new director, a move intended to strengthen corporate governance and leadership. Agenus Strengthens Board With New Director Appointment
• Neutral Sentiment: Reported short interest was listed at zero shares with a zero-day days-to-cover ratio, but the accompanying “NaN” change indicates the data may be incomplete or unreliable. It does not provide a meaningful short-squeeze signal.
• Negative Sentiment: Although near-term estimates improved, HC Wainwright lowered its EPS forecasts for FY2027 through FY2030, including FY2029 to a loss of $0.58 per share and FY2030 to a loss of $0.31. The revisions highlight continued uncertainty about Agenus’ longer-term path to profitability.
• Negative Sentiment: Agenus previously reported a quarterly EPS loss that was worse than analysts expected, despite revenue slightly exceeding forecasts. The company remains loss-making, which could limit the impact of the bullish price target.
• Negative Sentiment: Agenus reported no material changes to its previously disclosed risk factors, meaning investors continue to face the company’s existing regulatory, clinical, financing and execution risks. Agenus Risk Factor Update

About Agenus

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.